SCHIZOPHRENIFORM DISORDERS

This completed study tested Igalmi, a fast-dissolving film placed under the tongue, for managing frequent agitation in people with schizophrenia or bipolar disorder. 29 adults received the drug as needed for 7 days in a clinic. Researchers looked for signs that the drug might sto…

This study tested whether delivering coordinated specialty care (CSC) via telehealth works as well as standard in-person care for young people (ages 16–35) with early psychosis. Over 12 months, researchers tracked hospitalizations and engagement in 74 participants. The goal was t…

This Phase 3 trial tested a sublingual film containing dexmedetomidine (BXCL501) to quickly reduce agitation in 380 adults with schizophrenia or related disorders. Participants received either the drug or a placebo film, and researchers measured changes in agitation symptoms over…

This study tested an investigational medication called BXCL501 (dexmedetomidine) given as a film under the tongue for episodes of agitation in people with schizophrenia, schizoaffective disorder, or bipolar disorder. The trial included 452 adults aged 18-75 and compared the drug …

This study investigates how a medication called lorazepam, which boosts the calming brain chemical GABA, changes emotional brain activity in people with psychosis. Participants aged 16–60 with conditions like schizophrenia or bipolar disorder, along with healthy volunteers, will …

This study looked at how well patients, their family members, and doctors agree when rating agitation episodes in people with bipolar disorder or schizophrenia. Thirty-three adults received a treatment called BXCL501, and researchers compared different questionnaires to see which…

This study tested whether sending text message reminders and support to young people with psychosis after an emergency room visit helps them attend their first early psychosis appointment. 186 participants were enrolled. The goal was to see if a low-cost, youth-friendly approach …

This study tested a program called NAVIGATE, which provides coordinated care for youth and young adults (ages 14-35) who have had a first episode of psychosis. The goal was to see if NAVIGATE helps improve recovery, reduce hospital stays, and lower healthcare costs compared to st…

This study looked at how people aged 18-30 with early psychosis process information about their surroundings, compared to those without a psychiatric diagnosis. Participants completed computer-based tasks and cognitive training. The goal was to better understand thinking patterns…